Dexmedetomidine in Splanchnic Nerve Neurolysis
CompletedNot applicableNCT05291364
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Malignancy related abdominal and pelvic pain can be debilitating and affects survival as well as quality of life. Pain from cancer and its treatments can result in anxiety, depression, fear, anger, helplessness, and hopelessness, and those with both pain and depression have an amplification of disability and poor quality of life Pancreatic and other upper abdominal organ malignancies can produce intense visceral pain syndromes that are frequently treated with splanchnic nerve neurolysis (SNN) or celiac plexus neurolysis (CPN). Dexmedetomidine is a selective alpha two adreno-receptor agonist. It provides dose-dependent sedation, analgesia, sympatholysis, and anxiolysis without relevant respiratory depression. Dexmedetomidine is used as adjuvant to LA drugs in peripheral nerve block, brachial plexus block and intrathecal anesthesia with satisfactory results. The aim of this study is to evaluate effect of addition of dexmedetomidine as an adjuvant to alcohol and local anesthetics for chemical neurolysis to control pain in patients with intra-abdominal malignancy.
Study details
- Official title
- The Effectiveness of Adding Dexmedetomidine to Alcohol in Splanchnic Nerve Neurolysis for the Treatment of Intra-Abdominal Cancer Pain.
- Conditions
- Interventions
- Drug: Group 1
- Drug: Group 2
- Sponsor
- Minia University
- Start date
- 2020-09-30
- Primary completion
- 2022-06-30
- Sex
- All
- Age range
- from 25 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patient diagnosed to have abdominal malignancy aged 25 to 70 years old * Fully conscious * Patient has no hematological disease or coagulation abnormality. * Patient has no history of mental illness * Patient with persistent and moderate to severe abdominal pain visual analogue scale score \> 4. Exclusion Criteria: * Patient refusal of the procedure * Extremes of age * Patients with psychiatric disorders * Patient diagnosed to have any coagulation defect or bleeding tendency * Patients with cardiopulmonary significant condition * Skin infection or wounds at site of proposed needle insertion site
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05291364